Ladenburg Thalmann Financial Services’s Cymabay Therapeutics CBAY Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-358	Closed	-$2K	–	5553
2019 Q3	$2K	Hold	358	–	–	﹤0.01%	5026
2019 Q2	$2K	Hold	358	–	–	﹤0.01%	5021
2019 Q1	$5K	Sell	358 -2	-0.6%	-$21	﹤0.01%	4687
2018 Q4	$2K	Hold	360	–	–	﹤0.01%	4947
2018 Q3	$4K	Buy	360 +60	+20%	+$745	﹤0.01%	4715
2018 Q2	$4K	Hold	300	–	–	﹤0.01%	4699
2018 Q1	$4K	Sell	300 -1,435	-83%	-$17.8K	﹤0.01%	4699
2017 Q4	$16K	Hold	1,735	–	–	﹤0.01%	3934
2017 Q3	$14K	Sell	1,735 -4,700	-73%	-$31.8K	﹤0.01%	3906
2017 Q2	$37K	Hold	6,435	–	–	﹤0.01%	3226
2017 Q1	$28K	Buy	6,435 +5,000	+348%	+$14.3K	﹤0.01%	3330
2016 Q4	$2K	Buy	+1,435	New	+$2.53K	﹤0.01%	4565

Other funds holding CBAY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CBAY Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 358 shares — an estimated $2K sold.

Ladenburg Thalmann Financial Services first reported a position in CBAY in Q4 2016 and held it in 12 quarters. The position peaked at $37K in Q2 2017. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

Ladenburg Thalmann Financial Services reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 358 Cymabay Therapeutics shares in Q4 2019, an estimated $2K.
Ladenburg Thalmann Financial Services first reported a position in Cymabay Therapeutics in Q4 2016 and held it in 12 quarters.
Ladenburg Thalmann Financial Services's Cymabay Therapeutics position peaked at $37K in Q2 2017.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.